ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury

Barchart · 3d ago

EINDHOVEN, the Netherlands, Sept. 03, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, today announces the first implant in the EIGER clinical feasibility study evaluating the investigational ARC-IM® System for restoring mobility in people with subacute or chronic spinal cord injury (SCI).

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.